1. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

antibody

" in MedChemExpress (MCE) Product Catalog:

2311

Inhibitors & Agonists

4

Screening Libraries

182

Fluorescent Dye

190

Biochemical Assay Reagents

54

Peptides

17

MCE Kits

1843

Inhibitory Antibodies

13

Natural
Products

2

Recombinant Proteins

10

Isotope-Labeled Compounds

3711

Antibodies

264

Click Chemistry

35

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99018

    antibody ANB 020

    Interleukin Related Cancer
    Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis .
    Etokimab
  • HY-P99289

    antibody hLL 2; Anti-Human CD22 Recombinant antibody

    CD22 Inflammation/Immunology Cancer
    Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
    Epratuzumab
  • HY-P99352

    Anti-MSLN antibody

    Mesothelin Cancer
    Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .
    Anetumab
  • HY-P99271

    Anti-Human F3 Recombinant antibody

    ADC Antibody Cancer
    Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors .
    Tisotumab
  • HY-P99296

    CNTO 95; Anti-Human CD51 Recombinant antibody

    EGFR Cancer
    Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .
    Intetumumab
  • HY-P99313

    Anti-Human IGHE Recombinant antibody

    Apoptosis Inflammation/Immunology
    Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
    Quilizumab
  • HY-P99292

    HuZAF; Anti-Human IFNG Recombinant antibody

    IFNAR Inflammation/Immunology
    Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
    Fontolizumab
  • HY-P99144A

    PD-1/PD-L1 Inflammation/Immunology
    Anti-Mouse PD-1 Antibody (S-5001) is an anti-mouse PD-1 IgG1 antibody inhibitor.
    Anti-Mouse PD-1 Antibody (S-5001)
  • HY-P99372

    Anti-NCAM1/ CD56 Reference antibody (lorvotuzumab)

    ADC Antibody Cancer
    Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
    Lorvotuzumab
  • HY-P99324

    Anti-Human EGFR Recombinant antibody

    EGFR Apoptosis Cancer
    Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
    Tomuzotuximab
  • HY-P99374

    Anti-TSPAN26/CD37 Reference antibody (naratuximab)

    ADC Antibody Cancer
    Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
    Naratuximab
  • HY-P99295

    RG 7160; RO 5083945; Anti-EGFR Recombinant antibody

    EGFR Cancer
    Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
    Imgatuzumab
  • HY-P99328

    Anti-EPCAM Recombinant antibody; huKS-IL2

    Interleukin Related Inflammation/Immunology Cancer
    Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
    Tucotuzumab
  • HY-P9916

    Anti-Human IL6Rα, Human antibody

    Interleukin Related Inflammation/Immunology Cancer
    Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis .
    Sarilumab
  • HY-P99269

    BIBH 1; Anti-Human FAP Recombinant antibody

    FAP Cancer
    Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
    Sibrotuzumab
  • HY-P9917
    Tocilizumab
    20+ Cited Publications

    Anti-Human IL6R, Humanized antibody

    Interleukin Related Inflammation/Immunology Cancer
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
    Tocilizumab
  • HY-P9914

    Anti-Human C5, Humanized antibody

    Complement System Cardiovascular Disease Cancer
    Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .
    Eculizumab
  • HY-P99330

    Anti-Human VEGFA Recombinant antibody; RO5520985

    VEGFR Tie Cancer
    Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
    Vanucizumab
  • HY-P99263
    Inclacumab
    1 Publications Verification

    Anti-Human selectin P Recombinant antibody

    P-selectin Cardiovascular Disease
    Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
    Inclacumab
  • HY-P99293

    IDEC 114; Anti-Human CD80 Recombinant antibody

    CD28 Cancer
    Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
    Galiximab
  • HY-P99275
    Patritumab
    1 Publications Verification

    Human Anti-ERBB3 Recombinant antibody

    EGFR Akt ERK PARP Survivin Cancer
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
    Patritumab
  • HY-P9915
    Daratumumab
    1 Publications Verification

    Anti-Human CD38, Human antibody

    CD38 ADC Antibody Inflammation/Immunology Cancer
    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
    Daratumumab
  • HY-P99315

    BG 9588; Anti-Human CD40L Recombinant antibody

    TNF Receptor Inflammation/Immunology
    Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .
    Ruplizumab
  • HY-P99288

    Pamrevlumab; Anti-Human CTGF Recombinant antibody

    Apoptosis Cancer
    FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
    FG-3019
  • HY-P99270

    CS-1008; Anti-Human TRAIL-R2 Recombinant antibody

    Apoptosis Cancer
    Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
    Tigatuzumab
  • HY-P99252

    Anti-Human CD6 Recombinant antibody

    CD6 Infection Inflammation/Immunology
    Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
    Itolizumab
  • HY-P99294

    AMG 479; Human Anti-IGF1R Recombinant antibody

    IGF-1R Cancer
    Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
    Ganitumab
  • HY-P99785

    HLX20

    PD-1/PD-L1 Cancer
    Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
    Opucolimab
  • HY-P99256

    SCH 900222; MK 3222; Anti-Human IL23 Recombinant antibody

    Interleukin Related Inflammation/Immunology Cancer
    Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
    Tildrakizumab
  • HY-P990055

    EGFR Cancer
    Nezutatug is an anti-HER3 antibody, and used for cancer research .
    Nezutatug
  • HY-P990335

    Others ANGPTL Inflammation/Immunology
    Anti-ANGPTL4 Antibody
  • HY-P990336

    Others ANGPTL Inflammation/Immunology
    Anti-ANGPTL8 Antibody
  • HY-P99336

    BI-RR 0001; Anti-Human IL6 Recombinant antibody

    Integrin Neurological Disease Inflammation/Immunology
    Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
    Enlimomab
  • HY-P99234

    Interleukin Related ADC Antibody Cancer
    Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
    Pivekimab
  • HY-P99332

    Anti-Human CD3E Recombinant antibody; HuM291

    Apoptosis Inflammation/Immunology Cancer
    Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
    Visilizumab
  • HY-P99455

    EMB-01

    EGFR c-Met/HGFR Cancer
    Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .
    Bafisontamab
  • HY-P99702

    BCD-089

    Interleukin Related Inflammation/Immunology
    Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
    Levilimab
  • HY-P99825

    TNF Receptor Neurological Disease Inflammation/Immunology
    Relfovetmab is an anti-NGF monoclonal antibody (mAb) .
    Relfovetmab
  • HY-P99453

    ADC Antibody Cancer
    Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
    Azintuxizumab
  • HY-P9996

    LY3434172

    PD-1/PD-L1 Cancer
    Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research .
    Reozalimab
  • HY-P99298

    RG 7417; TNX 234; Anti-CFD Recombinant antibody

    Complement System Inflammation/Immunology
    Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
    Lampalizumab
  • HY-P99232

    5F9 Monoclonal antibody

    Guanylate Cyclase Cancer
    Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody .
    Indusatumab
  • HY-P99376
    Narsoplimab
    1 Publications Verification

    OMS 721; Anti-MASP2 Reference antibody (narsoplimab)

    SARS-CoV Infection
    Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
    Narsoplimab
  • HY-P99371

    AK002; Anti-Siglec-8 Reference antibody (lirentelimab)

    Apoptosis Inflammation/Immunology
    Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
    Lirentelimab
  • HY-P99360

    Anti-AXL/UFO Reference antibody (enapotamab)

    TAM Receptor Cancer
    Enapotamab is an anti-AXL/UFO reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates .
    Enapotamab
  • HY-P9980

    GSK2857914

    TNF Receptor ADC Antibody Cancer
    Belantamab (GSK2857914) is a humanised IgG1 anti-BCMA (TNFRSF17) monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin .
    Belantamab
  • HY-P9997

    ANB030

    PD-1/PD-L1 Cancer
    Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .
    Rosnilimab
  • HY-P99784

    Filovirus Infection
    Porgaviximab is a monoclonal antibody that can be used Ebola infection research .
    Porgaviximab
  • HY-P990786

    FLT3 ADC Antibody Cancer
    Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3, and can be used for acute myelogenous leukemia .
    Anti-FLT3 Antibody (AGS62P)
  • HY-111965

    anti-EFNA4-ADC

    Antibody-Drug Conjugates (ADCs) DNA Alkylator/Crosslinker Antibiotic Apoptosis Cancer
    PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody, ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts .
    PF-06647263

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: